Ishita Drugs & Industries Ltd. (BSE: 524400) is an Ahmedabad, Gujarat-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹22 Cr, it ranks #4,374 by market cap among the 6,197 Indian listed companies on FinBizNet, and #77 of 86 in Medicinal Chemicals and Botanical Products. At ₹72.76 (as of 16 Nov 2026), the share price is 19.9% below its 52-week high of ₹90.85 and 10.2% above its 52-week low of ₹66.00. The share price is up 1.6% over one year and up 2.2% over three months.
| Current Price | ₹72.76 |
|---|---|
| Market Cap | ₹22 Cr |
| BSE Code | 524400 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 28 |
| Return on Equity | 6.96% |
| Return on Assets | 3.03% |
| 52-Week Range | ₹66.00 – ₹90.85 |
| 1-Year Price Change | +1.6% |
| 3-Month Price Change | +2.2% |
| Beta (1Y) | -0.05 |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.ishitadrugs.com |
Delivery averaged 92.9% of traded volume across 14 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Ishita Drugs and Industries Limited manufactures and sells active pharma ingredients (APIs), fine chemicals, drug intermediates, and excipients in India and internationally. The company offers APIs, such as sulfa drugs/sulfonamides, vitamins, fluoro quinolones, antibiotics, anthelmintics, iodides and citrates, food additives/excipients, and others. It also provides contract manufacturing services for various drug intermediates, fine chemicals, or specialty chemicals. Ishita Drugs and Industries Limited was incorporated in 1992 and is based in Ahmedabad, India.
1. Pharmaceutical Business-This segment manufactures and markets various active pharma ingredients, drug intermediates, excipients, finished dosage forms, and fine chemicals.
1. Pharmaceutical Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Ishita Drugs & Industries Ltd. | ₹22 Cr | 28 | 6.96% | — | +1.6% |
Listed by market capitalisation. Ratios are shown for context only.
Ishita Drugs & Industries Ltd. is trading at ₹72.76, with a market capitalisation of ₹22 Cr.
Ishita Drugs & Industries Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Ishita Drugs & Industries Ltd. has a P/E of 28 and a return on equity of 6.96%.
Ishita Drugs & Industries Ltd. is listed on the BSE under the scrip code 524400.
Ishita Drugs & Industries Ltd.'s share price is up 1.6% over one year and up 2.2% over three months. Its 52-week range is ₹66.00 to ₹90.85.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.